Skip to main content
    • Aa
    • Aa

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

  • Michelle Kramer (a1), Robert Litman (a2), David Hough (a1), Rosanne Lane (a1), Pilar Lim (a1), Yanning Liu (a1) and Mariëlle Eerdekens (a3)
  • DOI:
  • Published online: 27 November 2009

We evaluated the efficacy and safety of the investigational long-acting injectable antipsychotic agent paliperidone palmitate (PP) in the treatment of schizophrenia. Patients were randomized to receive gluteal injections of placebo or PP (50 or 100 mg eq., fixed doses), without oral supplementation, on days 1, 8, and 36 (9-wk, double-blind phase) in this phase 2b study. Patients (n=197, intent-to-treat analysis set) were 62% men, mean (s.d.) age 39 (10) yr, with a baseline mean (s.d.) Positive and Negative Syndrome Scale (PANSS) total score of 87.0 (12.5). Mean (s.d.) PANSS total scores showed significant improvement at endpoint (primary measure) for both the PP 50 mg eq. [−5.2 (21.5)] and PP 100 mg eq. [−7.8 (19.4)] groups, vs. placebo [6.2 (18.3)] (p⩽0.001, each dose vs. placebo). This improvement was detected by day 8 and maintained to endpoint (p⩽0.011) for both doses. In the safety analysis set (n=247), fewer PP-treated patients (2%) discontinued for treatment-emergent adverse events vs. placebo-treated (10%). Rates of treatment-emergent extrapyramidal syndrome-related adverse events were comparable between active treatment and placebo, with the exception of parkinsonism-related disorders (50 mg eq. 5%, 100 mg eq. 8%, placebo 1%). Results of other safety measures suggest PP to be generally well-tolerated. Throughout the study, investigators rated injection-site pain as absent (56–71%), mild (24–39%), moderate (2–12%), or severe (0–2%). PP (50 and 100 mg eq. doses) administered as a gluteal intramuscular injection was efficacious and generally tolerated in these patients with acute symptomatic schizophrenia.

Corresponding author
Address for correspondence: Dr M. Kramer, 3210 Merryfield Row, San Diego, CA92121, USA. Tel.: 858 784-3203Fax: 858 450-2090Email:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

DB Allison , KR Fontaine , M Heo , JL Mentore , (1999). The distribution of body mass index among individuals with and without schizophrenia. Journal Clinical Psychiatry 60, 215220.

NC Andreasen (1995). Symptoms, signs, and diagnosis of schizophrenia. Lancet 346, 477481.

TR Barnes (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672676.

Y Bloch , S Mendlovic , S Strupinsky , A Altshuler , (2001). Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? Journal Clinical Psychiatry 62, 855859.

M Byerly , R Fisher , K Whatley , R Holland , (2005). A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Research 133, 129133.

M Davidson , R Emsley , M Kramer , L Ford , (2007). Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): Results of a 6-week, randomized, placebo-controlled study. Schizophrenia Research 93, 117130.

GL Hamann , TM Egan , BG Wells , JE Grimmig (1990). Injection site reactions after intramuscular administration of haloperidol decanoate 100 mg/mL. Journal Clinical Psychiatry 51, 502504.

D Hough , JP Lindenmayer , S Gopal , R Melkote , (2009). Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 33, 10221031.

DA Johnson , G Pasterski , JM Ludlow , K Street , (1983). The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatrica Scandinavica 67, 339352.

J Kane , F Canas , M Kramer , L Ford , (2007). Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophrenia Research 90, 147161.

P Karlsson , E Dencker , E Mannaert , S Boom , (2006). Pharmacokinetics, dopamine D2 and serotonin 5-HT2A receptor occupancy and safety profile of paliperidone extended-release in healthy subjects. Schizophrenia Research 81 (Suppl. 1), 8586.

SR Kay , A Fiszbein , LA Opler (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261276.

SJ Keith , JM Kane (2003). Partial compliance and patient consequences in schizophrenia: our patients can do better. Journal Clinical Psychiatry 64, 13081315.

M Kramer , G Simpson , V Maciulis , S Kushner , (2007). Paliperidone extended release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Journal Clinical Psychopharmacology 27, 6–14.

TP Laughren (2001). The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. European Psychiatry 16, 418423.

S Leucht , JM Kane , W Kissling , J Hamann , (2005). What does the PANSS mean? Schizophrenia Research 79, 231238.

JP Lindenmayer , R Bernstein-Hyman , S Grochowski (1994). A new five factor model of schizophrenia. Psychiatry Quarterly 65, 299322.

JP Lindenmayer , K Jarboe , CA Bossie , Y Zhu , (2005). Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. International Clinical Psychopharmacology 20, 213221.

SR Marder , JM Davis , G Chouinard (1997). The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal Clinical Psychiatry 58, 538546.

SR Marder , M Kramer , L Ford , E Eerdekens , (2007). Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biological Psychiatry 62, 13631370.

HA Nasrallah (2007). The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatrica Scandinavica 115, 260267.

D Robinson , MG Woerner , JM Alvir , R Bilder , (1999). Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Archives General Psychiatry 56, 241247.

A Sagie , MG Larson , RJ Goldberg , JR Bengtson , (1992). An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study). American Journal Cardiology 70, 797801.

MN Samtani , A Vermeulen , K Stuyckens (2009). Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clinical Pharmacokinetics 48, 585600.

RJ Wyatt (1991). Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin 17, 325351.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

The International Journal of Neuropsychopharmacology
  • ISSN: 1461-1457
  • EISSN: 1469-5111
  • URL: /core/journals/the-international-journal-of-neuropsychopharmacology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *